. Author manuscript; available in PMC: 2022 Feb 18.

Published in final edited form as: Obesity (Silver Spring). 2020 Sep;28(9):1678–1686. doi: 10.1002/oby.22936

Table 3.

Cancer Mortality by study arm in 4,859 Look AHEAD participants

	DSE		ILI
	Number of Events	Rate^*	Number of Events	Rate^*	HR (95% Cl)	P-value
Cancer Type	Number of Events	Rate^*	Number of Events	Rate^*	HR (95% Cl)	P-value
All Cancers	85	3.2	80	3.0	0.92(0.68, 1.25)	0.59
Obesity Related^¶	45	1.7	42	1.6	0.91(0.60, 1.39)	0.67
Non-Obesity Related	40	1.5	38	1.4	0.93(0.60, 1.45)	0.74
Men
All Cancers	50	4.8	39	3.6	0.75(0.50, 1.15)	0.19
Obesity Related^¶	24	2.3	17	1.6	0.69(0.37,1.28)	0.24
Non-Obesity Related	26	2.5	22	2.1	0.82(0.46, 1.44)	0.48
Women
All Cancers	35	2.2	41	2.6	1.15(0.73, 1.81)	0.54
Obesity Related^¶	21	1.3	25	1.6	1.17(0.65, 2.08)	0.60
Non-Obesity Related	14	0.9	16	1.0	1.13(0.55,2.31)	0.74

DSE: Diabetes Support and Education. ILI: Intensive Lifestyle Intervention. HR: hazard ratio

Rate per 1,000 person-years

^¶

Included esophagus, colon, rectum, kidney, pancreas, stomach, liver, gallbladder, thyroid, and multiple myeloma in men and women, and additional uterus, ovary, post-menopausal breast in women.